Formulation Development
Halda Therapeutics Announces Acquisition by Johnson & Johnson
Halda Therapeutics recently announced it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire Halda for $3.05 billion, payable in…
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
Moleculin Biotech, Inc. recently provided an enrollment update with 60% of the target number of subjects for the first planned interim unblinding of data having consented…
Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension to the FDA
Cereno Scientific, an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, recently announced the submission of…
Nanoform Finland Plc | Inside Information
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, today announced that it has received a Commercial cGMP Manufacturing License from FIMEA (Finnish…
Abzena and Mabqi Announce Strategic Partnership to Offer Integrated Discovery Through Development Solution
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and development of fully human…
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program
HCW Biologics Inc. recently announced the data presented for their tetra-valent, second-generation T-Cell Engager (“TCE”) Program based on their novel TRBC platform technology, at the…
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator
Assembly Biosciences, Inc. recently announced Phase 1b clinical data for its next-generation investigational capsid assembly modulator (CAM) ABI-4334 featured in a late-breaking poster presentation at…
Ocular Therapeutix Achieves Target Randomization of 555 Subjects in SOL-R
Ocular Therapeutix, Inc. recently announced that its SOL-R registrational trial of AXPAXLI™ (also known as OTX-TKI) in wet age-related macular degeneration (wet AMD) has achieved…
Argonaut Manufacturing Services Appoints Rick Hancock as CEO to Lead Next Phase of Growth
Argonaut Manufacturing Services recently announced the appointment of Rick Hancock as Chief Executive Officer (CEO). Rick is a biotechnology executive with more than 40 years…
Enara Bio’s DARKFOX Discovery Propels ENA101, the First Ever Bispecific T Cell Engager Targeting a Cancer-Specific Dark Antigen, Into IND-Enabling Studies
Enara Bio recently will unveil its newly discovered cancer-specific target DARKFOX as the first in a new category of validated Dark Antigens in an oral…
Eder Therapeutics & XCubeBio Partner to Establish Joint NewCo for Global Development & Future Market Entry Activities
Eder Therapeutics, a Canadian biopharmaceutical company focused on rare genetic disorders and XCubeBio AG, a biotechnology platform company focused on accelerating successful international market entry…
Rein Therapeutics Receives FDA Clearance to Resume Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics recently announced the US FDA has lifted the full clinical hold on the Company’s Phase 2 “RENEW” trial evaluating LTI-03 in patients with…
Piramal Pharma Solutions Formalizes Partnership With IntoCell, Expanding its Payload-Linker Platform & Bioconjugate Capabilities
Piramal Pharma Solutions has signed a Memorandum of Understanding (MOU) to solidify its strategic partnership and explore potential collaboration opportunities in ADC development with IntoCell Inc.…
4DMT Announces Exclusive License Agreement With Otsuka Pharmaceutical for Development & Commercialization of 4D-150 in Asia-Pacific
4D Molecular Therapeutics recently announced a strategic partnership with Otsuka Pharmaceutical Co., Ltd. (Otsuka) to develop and commercialize 4D-150 for the treatment of wet age-related…
Clearmind Medicine Advances Fight Against Cocaine Addiction With Publication of US Patent Application for its Non-Hallucinogenic Neuroplastogen MEAI Therapy
Clearmind Medicine Inc. recently announced the publication of a US patent application expanding coverage of its non-hallucinogenic proprietary compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of…
Zag Bio Launches With $80 Million Financing to Advance Thymus-Targeted Medicines for Autoimmune Diseases
Zag Bio, Inc. recently announced the company’s launch with $80 million in financing, including a recently closed Series A financing. Polaris Partners founded and incubated Zag…
Slingshot Biosciences & Cellares Combine TruCytes Biomarker Controls With Cell Q Platform to Enhance Quality & Automation in Cell Therapy Manufacturing
Slingshot Biosciences recently announced a strategic collaboration with Cellares that integrates Slingshot’s TruCytes Biomarker controls into Cellares’ Cell Q, the industry’s first fully automated quality-control…
Zenas BioPharma Announces Positive Results From Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
Zenas BioPharma, Inc. recently announced positive results from the Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis (RMS). Obexelimab met the primary endpoint,…
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today presented new preclinical data…
NodThera Announces First Patients Dosed in RESOLVE-2 Clinical Trial Evaluating Oral NT-0796 in Combination With a GLP-1 Receptor Agonist
NodThera, a clinical-stage biotech pioneering a paradigm shift in the treatment of chronic inflammatory diseases through NLRP3 inhibition, today announced that the first patients have…
